还原型谷胱甘肽减轻化疗毒副反应的疗效观察  

Efficacy of reduced glutathione in the depletion toxicity during chemotherapy

作　　者：钱屹崟[1] 徐新才[1] 邵利坚[1] 符炜[1] 

机构地区：[1]苏州大学附属常熟市第一人民医院肿瘤科,江苏常熟215500

出　　处：《现代肿瘤医学》2008年第2期286-288,共3页Journal of Modern Oncology

摘　　要：目的:观察还原型谷胱甘肽(GSH)对肿瘤患者化疗所致骨髓功能、肝功能损害的影响。方法:将102例患者随机分为两组,预防组(52例),在化疗同时予以GSH。对照组(50例),单纯化疗。同时观察两组在骨髓抑制(白细胞)、肝功能损害(谷丙转氨酶)上的差异。结果:预防组和对照组白细胞下降分别是46.15%(24/52)和72.00%(36/50);Ⅰ度-Ⅳ度白细胞减少分比分别为40.98%(84/205)和67.55%(102/151);影响化疗分别为5.37%(11/205)和17.22%(26/151),均有显著性差异(P<0.01),化疗后ALT异常预防组和对照组分别为34.55%(19/55)和74%(37/50);ALT异常分别为20%(41/205)和65.56%(99/151);影响化疗分别为3.41%(7/205)和19.21%(29/151),均有显著性差异(P<0.01)。结论:GSH用于缓解恶性肿瘤患者化疗所致毒副反应疗效显著,在保证化疗的安全性、有效性的同时也提高了患者的生活质量。Objective：To observe the effect of GSH on poison and auxiliary respond among cancer patients with chemotherapy. Methods：All 102 patients with malignant tumors were randomly divided into two groups . Prevention group （52 cases） received both chemotherapy and GSH during treatment . The control group （50 cases） only received chemotherapy. To odserve the difference of two groups on marrow restraint （ only leucocyte ） and hepatotoxicity . Results：In the prevention group and control group, the rates of leucocyte decreased were 46.15 % （24/52） and 72.00% （36/50） ;the rates of Ⅰ°- Ⅳ° leukopenia respectively were 40.98% （84/205） and 67.55 % （102/ 151 ） ; the delaying rates of cycle of suspended chemotherapy respectively were 5.37% （ 11/205 ） and 17.22% （26/ 151 ） ; all showed significant difference （ P 〈 0.01 ）. After chemotherapy , the rates of liver dysfunction with highter ALT respectively were 34.55 % （ 19/55 ） and 74% （37/50） ; the rates of hepatotoxicity in whole chemotherapy periods respectively were 20% （41/205）and 65.56% （99/151） ; the delaying rates of cycle of suspended chemotherapy respectively were 3.41% （7/205）and 19.21% （29/151）, there were significant difference （P 〈 0.01 ）. Conclusion： GSH is effective in the depletion poison and auxiliary respond during chemotherapy to malignancy patients.

关 键 词：还原型谷胱甘肽 化疗 毒副反应 

分 类 号：R730.58[医药卫生—肿瘤]